ERAS and melanoma: Furthermore, HLA-A24 specific peptides of HER2/neu (15), tyrosinase in melanoma (16), CEA and MAGE-3 in gastrointestinal malignancies (17,18), SART-1 in oral squamous cell carcinoma (19), MUC5AC in pancreatic cancer (35), Eras in gastric cancer (36) and P53 in bladder cancer (20,21) had previously been used.